Organization (Academic)
CARDIFF UNIVERSITY
ClinicalTrials.gov lists CARDIFF UNIVERSITY as lead sponsor of 44 trials. It has 5 active development programs and 25 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Cardiff University, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers CARDIFF UNIVERSITY: 44 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (127)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 7 |
| COVID-19 | 5 |
| Inflammation | 5 |
| Sepsis | 5 |
| Colorectal Neoplasms | 4 |
Showing 5 of 127 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 6 |
| 2024 | 6 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 7 |
| 2020 | 11 |
| 2019 | 6 |
| 2018 | 9 |
| 2017 | 10 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (5)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PEMBROLIZUMAB | Anus Neoplasms | Phase 1 | 1 |
| PEMBROLIZUMAB | Rectal Neoplasms | Phase 1 | 1 |
| PEMBROLIZUMAB | Colorectal Neoplasms | Phase 1 | 1 |
| C19-A3 GNP | Diabetes Mellitus | Phase 1 | 1 |
| C19-A3 GNP | Diabetes Mellitus, Type 1 | Phase 1 | 1 |
Approved assets (25)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Synacthen (Tetracosactrin) | 1 |
| Perindopril | 1 |
| Eye drop solution | 1 |
| Atenolol | 1 |
| Bimatoprost | 1 |
Showing 5 of 25 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 43% hit target (n=14) | 18% on time (n=11) |
Journals published in (93)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 14 |
| Trials | 8 |
| International journal of paediatric dentistry | 4 |
| NeuroImage | 4 |
| PloS one | 4 |
Showing 5 of 93 journals.
Financing and grant events (17)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-08-04 | NIH grant | 522,882 | Reporter |
| 2025-04-12 | NIH grant | 473,249 | Reporter |
| 2024-12-23 | NIH grant | 318,085 | Reporter |
| 2024-09-05 | NIH grant | 130,646 | Reporter |
| 2024-06-26 | NIH grant | 531,177 | Reporter |
Showing 5 of 17 events.
Organization relationships (65)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| National Health Service Wales | Co sponsors trial with | 5 |
| King's College Hospital NHS Trust | Co sponsors trial with | 4 |
| University of Oxford | Co sponsors trial with | 3 |
| University Hospital Southampton NHS Foundation Trust | Co sponsors trial with | 3 |
| Imperial College London | Co sponsors trial with | 3 |
Showing 5 of 65 relationships.
Latest dated events (125)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-04 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 125 events.
Biomarker capability evidence (115)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| AQP4 | Trial collaborator | Named in trial inclusion criteria |
| BCHE | Trial collaborator | Named in trial inclusion criteria |
| BCR | Trial sponsor | Named in trial inclusion criteria |
| CRP | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 115 evidence rows.
Biomarkers this organization publishes on (1,232)
Shown in this order: most publications first.
Showing 5 of 1,232 biomarkers.
On Scientist.com
CARDIFF UNIVERSITY is listed as a research supplier in the Scientist.com network.
Service areas
Through its College of Biomedical and Life Sciences, Cardiff University offers expertise in medicinal chemistry, drug delivery, microbiology, pharmacology, physiology, and molecular biosciences. The Division of Molecular Biosciences focuses on the molecular mechanisms underpinning biological function. This Division has a broad strength that spans biochemistry, structural and synthetic biology, cell biology, molecular genetics and developmental biology. The groups within Molecular Biosciences focus on a variety of biological systems including Drosophila, yeast, Arabidopsis, tobacco...
Show the full description
Through its College of Biomedical and Life Sciences, Cardiff University offers expertise in medicinal chemistry, drug delivery, microbiology, pharmacology, physiology, and molecular biosciences.
The Division of Molecular Biosciences focuses on the molecular mechanisms underpinning biological function. This Division has a broad strength that spans biochemistry, structural and synthetic biology, cell biology, molecular genetics and developmental biology. The groups within Molecular Biosciences focus on a variety of biological systems including Drosophila, yeast, Arabidopsis, tobacco, Dictyostelium, and mammalian cells, and have a growing strength in the use of post-genomic and systems approaches to solve biological problems.
Research in the Cardiff School of Pharmacy and Pharmaceutical Sciences encompasses all facets of the study of pharmaceuticals. The School's four disciplines represent operational units providing platform knowledge and technical resource support. Research in the laboratory-based sciences covers a spectrum of disease areas including cancer, infection, cardiovascular, musculo-skeletal, respiratory and neurological disorders. This work seeks to identify fundamental mechanisms of disease and new pharmacological targets, the design of novel drug candidates and of innovative drug delivery systems. Complementing the activities of the laboratory sciences are academic staff engaged in understanding the social and psychological aspects of the medicines-patient interface, measuring patients’ quality of life and associated issues around medicines resource allocation.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Cardiff University on Scientist.com
For prices, more details, or to contact Cardiff University, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.